

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated July 17, 2025 (the “**Prospectus**”) issued by Nanjing Leads Biolabs Co., Ltd. (南京维立志博生物科技股份有限公司) (the “**Company**”).*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for any securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States. The Offer Shares may not be offered, sold, pledged or otherwise transferred within the United States, except pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to Rule 144A or another available exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

In connection with the Global Offering, Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited act as the Joint Sponsors; Morgan Stanley Asia Limited and CLSA Limited act as the Sponsor-Overall Coordinators and CMB International Capital Limited acts as the Overall Coordinator.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, July 25, 2025).



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 36,862,500 H Shares (taking into account the full exercise of the Offer Size Adjustment Option and subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 16,027,200 H Shares (as adjusted after reallocation)
Number of International Offer Shares	: 20,835,300 H Shares (taking into account the full exercise of the Offer Size Adjustment Option, as adjusted after reallocation and subject to the Over-allotment Option)
Offer Price	: HK\$35.00 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Hong Kong Stock Exchange trading fee of 0.00565%
Nominal value	: RMB1.00 per H Share
Stock code	: 9887

Joint Sponsors

Morgan Stanley



CITIC SECURITIES

Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Morgan Stanley



CITIC SECURITIES



Joint Bookrunners and Joint Lead Managers



Nanjing Leads Biolabs Co., Ltd. / 南京维立志博生物科技股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated July 17, 2025 (the “**Prospectus**”) issued by Nanjing Leads Biolabs Co., Ltd. (南京维立志博生物科技股份有限公司) (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock code	9887
Stock short name	LEADS BIOLABS-B
Dealings commencement date	July 25, 2025*

* *see note at the end of the announcement*

Price Information	
Final Offer Price	HK\$35.00
Offer Price Range	HK\$31.60 – HK\$35.00

Offer Shares and Share Capital	
Number of Offer Shares (taking into account the full exercise of the Offer Size Adjustment Option)	36,862,500 H Shares
Number of Offer Shares in Hong Kong Public Offering (as adjusted after reallocation)	16,027,200 H Shares
Number of Offer Shares in International Offering (taking into account the full exercise of the Offer Size Adjustment Option and as adjusted after reallocation)	20,835,300 H Shares
Number of issued Shares upon Listing (before any exercise of the Over-allotment Option)	193,362,500 Shares

The number of Offer Shares above is determined after taking into account the additional H Shares issued under the following Offer Size Adjustment Option.

Offer Size Adjustment Option (Upsize Option)	
Number of additional Shares issued under the option	4,808,100 H Shares
– Hong Kong Public Offering	N/A
– International Offering	4,808,100 H Shares

The Offer Size Adjustment Option has been fully exercised by the Overall Coordinators, pursuant to which the Company is issuing and allotting 4,808,100 additional H Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Final Offer Price.

Over-allocation	
No. of Offer Shares over-allocated (taking into account the full exercise of the Offer Size Adjustment Option)	12,821,700 H Shares
– International Offering	12,821,700 H Shares
<i>Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.</i>	
Proceeds	
Gross proceeds (Note)	HK\$1,290.2 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$(110.8) million
Net proceeds	HK\$1,179.3 million
<i>Note: Gross proceeds refers to the amount to which the issuer is entitled to receive, taking into account the full exercise of the Offer Size Adjustment Option, and without taking into account the Over-allotment Option. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus. In the event that the Over-allotment Option is exercised, the Company will adjust the allocation of the net proceeds on a pro rata basis. During the Track Record Period, the listing expenses of HK\$23.0 million has been charged to the consolidated statements of profit or loss of the Company.</i>	

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	323,706
No. of successful applications	73,406
Subscription level	3,494.78 times
Claw-back triggered	Yes
No. of Offer Shares initially available under the Hong Kong Public Offering	3,205,500
No. of Offer Shares reallocated from the International Offering	12,821,700
Final no. of Offer Shares under the Hong Kong Public Offering	16,027,200
% of final no. of Offer Shares under the Hong Kong Public Offering to the Global Offering	43.48%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	141
Subscription Level	40.78 times
No. of Offer Shares initially available under the International Offering	28,848,900
No. of Offer Shares reallocated to the Hong Kong Public Offering	12,821,700
Final no. of Offer Shares under the International Offering (taking into account the full exercise of the Offer Size Adjustment Option, as adjusted after reallocation and subject to the Over-allotment Option)	20,835,300
% of final no. of Offer Shares under the International Offering to the Global Offering	56.52%

*The Directors confirm that, to the best of their knowledge, information and belief, save for (a) a waiver from strict compliance with Rule 10.04 of the Listing Rules and written consents under paragraph 5(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to an existing shareholder and certain close associates of existing shareholders, and (b) consents under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected clients granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, the Supervisors, chief executive of the Company, AIC Parties, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, the Supervisors, chief executive of the Company, AIC Parties, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

¹ For details, please see “Others/Additional information” in this announcement.

The placees in the International Offering include the following:

Cornerstone Investors

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i> ^{Note 2}	<i>% of total issued Shares after the Global Offering</i> ^{Note 2}	<i>Existing shareholders or their close associates</i>
Loyal Valley Capital Advantage Fund III LP (“ Loyal Valley Fund III ”)	1,121,300	3.04%	0.58%	Yes
Golden Valley Global Limited	897,100	2.43%	0.46%	Yes
Golden Valley Value Select Master Fund (together with Loyal Valley Fund III and Golden Valley Global Limited, the “ LVC Entities ”)	897,100	2.43%	0.46%	Yes
Shanghai Gaoyi Asset Management Partnership (Limited Partnership) (上海高毅資產管理合夥企業(有限合夥)) (“ Shanghai Gaoyi ”) and Huatai Capital Investment Limited (“ HTCI ”) (in connection with Huatai Back-to-back TRS and Huatai Client TRS)	1,794,200	4.87%	0.93%	No
Perseverance Asset Management International (Singapore) Pte. Ltd.	448,500	1.22%	0.23%	No
TruMed Healthcare Master Fund	123,300	0.33%	0.06%	No
TruMed Health Innovation Fund LP	2,119,400	5.75%	1.10%	No
OrbiMed Genesis Master Fund, L.P.	1,401,700	3.80%	0.72%	No
The Biotech Growth Trust PLC	841,000	2.28%	0.43%	No

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i> ^{Note 2}	<i>% of total issued Shares after the Global Offering</i> ^{Note 2}	<i>Existing shareholders or their close associates</i>
Huang River Investment Limited	1,794,200	4.87%	0.93%	No
E Fund Management Co., Ltd. (易方達基金管理有限公司)	1,379,300	3.74%	0.71%	No
E Fund Management (Hong Kong) Co., Ltd. (易方達資產管理(香港)有限公司)	190,600	0.52%	0.10%	No
FORESIGHT GLOBAL SUPERIOR CHOICE SPC – GLOBAL SUPERIOR CHOICE FUND 1 SP (“ Foresight Funds GSC Fund 1 ”) and Foresight Global Superior Choice SPC – Vision Fund 1 SP (“ Vision Fund 1 ”)	1,121,300	3.05%	0.58%	No
Sage Partners Master Fund	897,100	2.43%	0.46%	No
Hankang Biotech Fund III, L.P.	224,200	0.61%	0.12%	Yes
Splendid Biotech Fund L.P.	224,200	0.61%	0.12%	Yes
Total	15,474,500	41.98%	8.00%	
<p><i>Notes:</i></p> <p>1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.</p> <p>2. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.</p>				

Allottee with Waiver/Consents Obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i> ^{Note 1}	<i>% of total issued Shares after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
Allottee with waiver from strict compliance with Rule 10.04 of the Listing Rules and consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Offer Shares by an existing shareholder ^{Note 2}				
Loyal Valley Fund III	1,121,300	3.04%	0.58%	Loyal Valley Fund III is an existing shareholder of the Company.

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares^{Note 1}</i>	<i>% of total issued Shares after the Global Offering^{Note 1}</i>	<i>Relationship</i>
<i>Allottee with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for Offer Shares by close associates of existing Shareholders^{Note 2}</i>				
Golden Valley Global Limited	897,100	2.43%	0.464%	Golden Valley Global Limited is a close associate of an existing shareholder of the Company.
Golden Valley Value Select Master Fund	897,100	2.43%	0.464%	Golden Valley is a close associate of an existing shareholder of the Company.
Splendid Biotech Fund L.P.	224,200	0.61%	0.116%	Splendid Biotech Fund L.P. is a close associate of an existing shareholder of the Company.
Hankang Biotech Fund III, L.P. (together with Splendid Biotech Fund L.P., the “ Hankang Entities ”)	224,200	0.61%	0.116%	Hankang Biotech Fund III, L.P. is a close associate of an existing shareholder of the Company.
Bosera Asset Management (International) Co., Limited (“ Bosera International ”)	40,000	0.11%	0.02%	Bosera International is a close associate of an existing shareholder of the Company.

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares^{Note 1}</i>	<i>% of total issued Shares after the Global Offering^{Note 1}</i>	<i>Relationship</i>
<i>Allotees with consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected client^{Note 3}</i>				
CITIC Securities International Capital Management Limited (“ CSI ”)	1,116,600	3.03%	0.58%	Connected client as a placee
China Asset Management (Hong Kong) Limited (“ China AM HK ”)	60,000	0.16%	0.03%	Connected client as a placee
UBS Asset Management (Singapore) Limited (“ UBS AM ”)	494,000	1.34%	0.26%	Connected client as a placee
<p><i>Notes:</i></p> <ol style="list-style-type: none"> <i>Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.</i> <i>The Company has applied for, and the Stock Exchange has granted, (i) a waiver from strict compliance with Rule 10.04 of the Listing Rules and a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Loyal Valley Fund III, an existing shareholder of Company, and (ii) a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to the LVC Entities, Hankang Entities and Bosera International, each a close associate of existing Shareholders of the Company, to permit the Company to allocate such Offer Shares in the International Offering to them and Bosera International. The allocation of Offer Shares to the aforementioned entities and Bosera International is in compliance with all the conditions under the consent granted by the Stock Exchange. For details, please refer to the section headed “Others/Additional Information” in this announcement below.</i> <i>For details of the consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocations to connected clients, please refer to the section headed “Others/Additional Information — Allocation of Offer Shares to connected clients with prior written consent under paragraph 5(1) of the Placing Guidelines” in this announcement.</i> 				

LOCK-UP UNDERTAKINGS

AIC Parties

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing ^{Note 1}	% of shareholding in the Company subject to lock-up undertakings upon Listing ^{Note 1}	Last day subject to the lock-up undertakings ^{Note 2}
Dr. Kang Xiaoqiang (“ Dr. Kang ”) ^{Notes 2, 3}	7,874,617 (including 3,937,309 H Shares)	2.66%	4.07%	July 24, 2026 ^{Note 4}
Dr. Lai Shoupeng (“ Dr. Lai ”) ^{Notes 2, 3}	6,384,821 (including 3,192,411 H Shares)	2.16%	3.30%	July 24, 2026 ^{Note 4}
Nanjing Lizhi Management & Consulting Center (Limited Partnership) (南京禮至企業管理諮詢中心 (有限合夥)) (“ Lizhi Partnership ”) ^{Notes 2, 3}	12,845,442 (including 6,422,721 H Shares)	4.35%	6.64%	July 24, 2026 ^{Note 4}
LeadsTech Limited ^{Notes 2, 3}	1,920,004 (including 960,002 H Shares)	0.65%	0.99%	July 24, 2026 ^{Note 4}
LeadsBio Limited ^{Notes 2, 3}	1,663,936 (including 1,200,000 H Shares)	0.81%	0.86%	July 24, 2026 ^{Note 4}
Total	30,688,820	10.63%	15.87%	

Notes:

1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
2. Dr. Kang is executive Director and Chief Executive Officer and general manager of the Company. Dr. Lai is executive Director, Chief Strategic Officer and executive vice president of the Company. Each of Lizhi Partnership, LeadsBio Limited and LeadsTech Limited is a share incentive platform of the Company. Please refer to the section headed “Substantial Shareholders” of the Prospectus for more information.

Immediately before completion of the Global Offering, Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio Limited and LeadsTech Limited were entitled to exercise voting rights of approximately 19.61% of the Company in aggregate pursuant to a concert party agreement entered into among the parties. Immediately following the completion of the Global Offering, Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio Limited and LeadsTech Limited will together control the voting rights of approximately 15.87% of the total issued share capital of our Company. Accordingly, Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio Limited and LeadsTech Limited are a group of AIC Parties and each of them is subject to the same lock-up as disclosed above.

3. *In view of the concert party agreement, each of Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio Limited and LeadsTech Limited is deemed to be interested in the interest of each other under the SFO.*
4. *The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws. In accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing Shareholders ends on July 24, 2026, being 12 months following the Listing Date.*

Cornerstone Investors

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Loyal Valley Fund III	1,121,300	0.76%	0.58%	January 24, 2026
Golden Valley Global Limited	897,100	0.61%	0.46%	January 24, 2026
Golden Valley Value Select Master Fund	897,100	0.61%	0.46%	January 24, 2026
Shanghai Gaoyi and HTCI (in connection with Huatai Back-to-back TRS and Huatai Client TRS)	1,794,200	1.21%	0.93%	January 24, 2026
Perseverance Asset Management International (Singapore) Pte. Ltd.	448,500	0.30%	0.23%	January 24, 2026
TruMed Healthcare Master Fund	123,300	0.08%	0.06%	January 24, 2026

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
TruMed Health Innovation Fund LP	2,119,400	1.43%	1.10%	January 24, 2026
OrbiMed Genesis Master Fund, L.P.	1,401,700	0.95%	0.72%	January 24, 2026
The Biotech Growth Trust PLC	841,000	0.57%	0.43%	January 24, 2026
Huang River Investment Limited	1,794,200	1.21%	0.93%	January 24, 2026
E Fund Management Co., Ltd. (易方達基金管理有限公司)	1,379,300	0.93%	0.71%	January 24, 2026
E Fund Management (Hong Kong) Co., Ltd. (易方達資產管理(香港)有限公司)	190,600	0.13%	0.10%	January 24, 2026
Foresight Funds GSC Fund 1	437,300	0.30%	0.23%	January 24, 2026
Vision Fund 1	684,000	0.46%	0.35%	January 24, 2026
Sage Partners Master Fund	897,100	0.61%	0.46%	January 24, 2026
Hankang Biotech Fund III, L.P.	224,200	0.15%	0.12%	January 24, 2026
Splendid Biotech Fund L.P.	224,200	0.15%	0.12%	January 24, 2026
Total	15,474,500	10.47%	8.00%	
<p><i>Notes:</i></p> <p>1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.</p> <p>2. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on January 24, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.</p>				

Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Nanjing Ennovation Raylight Healthcare Investment Partnership (Limited Partnership) (南京恩然瑞光健康產業投資合夥企業(有限合夥)) ^{Note 3}	5,901,290 (including 2,950,645 H Shares)	2.00%	3.05%	July 24, 2026
Nanjing Jieyuan Growth Venture Capital Partnership (Limited Partnership) (南京捷源成長創業投資合夥企業(有限合夥)) ^{Note 3}	2,974,369 (including 2,974,369 H Shares)	2.01%	1.54%	July 24, 2026
Nanjing Enjie Venture Capital Partnership (Limited Partnership) (南京恩捷創業投資合夥企業(有限合夥)) ^{Note 3}	1,332,237 (including 666,119 H Shares)	0.45%	0.69%	July 24, 2026
Nanjing Ennovation Chengfeng Entrepreneurship Investment Partnership (Limited Partnership) (南京恩然呈豐創業投資合夥企業(有限合夥)) ^{Note 3}	937,500	–	0.48%	July 24, 2026
Nanjing Jiakang Ruizhen Venture Investment Partnership (Limited Partnership) (南京佳康瑞臻創業投資合夥企業(有限合夥)) ^{Note 3}	684,016	–	0.35%	July 24, 2026
Suzhou Jianxin Hankang Venture Investment Partnership Enterprise (Limited Partnership) (蘇州建信漢康創業投資合夥企業(有限合夥)) (“Suzhou Hankang”) ^{Note 4}	6,853,584 (including 6,853,584 H Shares)	4.64%	3.54%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Beijing Hankang Jianxin Venture Investment Co., Ltd. (北京漢康建信創業投資有限公司) (“ Beijing Hankang ”) ^{Note 4}	3,036,869 (including 3,036,869 H Shares)	2.06%	1.57%	July 24, 2026
Hankang Small and Medium Enterprises Development Fund (Weifang) Partnership Enterprise (Limited Partnership) (漢康中小企業發展基金(濰坊)合夥企業(有限合夥)) (“ Hankang SME ”) ^{Note 4}	2,682,372 (including 999,178 H Shares)	0.68%	1.39%	July 24, 2026
Loyal Valley Fund III ^{Note 5}	9,991,770	–	5.17%	July 24, 2026
Shanghai Leyong Investment Partnership Enterprise (Limited Partnership) (上海樂永投資合夥企業(有限合夥)) (“ Shanghai Leyong ”) ^{Note 5}	1,998,356	–	1.03%	July 24, 2026
Shanghai Jishi Lemei Private Equity Investment Fund Partnership Enterprise (Limited Partnership) (上海濟世樂美私募投資基金合夥企業(有限合夥)) (“ Shanghai Jishi Lemei ”) ^{Note 5}	1,579,970 (including 895,954 H Shares)	0.61%	0.82%	July 24, 2026
Beijing Chongshan Yuanwei Investment Center (Limited Partnership) (北京重山遠為投資中心(有限合夥))	3,261,914 (including 3,261,914 H Shares)	2.21%	1.69%	July 24, 2026
Ningbo Huaige Gongxin Venture Investment Partnership Enterprise (Limited Partnership) (寧波懷格共信創業投資合夥企業(有限合夥)) ^{Note 6}	4,611,383 (including 4,611,383 H Shares)	3.12%	2.38%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Jingning Huaige Ruixin Venture Investment Partnership Enterprise (Limited Partnership) (景寧懷格瑞信創業投資合夥企業(有限合夥)) ^{Note 6}	1,665,296 (including 832,648 H Shares)	0.56%	0.86%	July 24, 2026
Chengdu Huaige Guosheng Venture Investment Partnership (Limited Partnership) (成都懷格國生創業投資合夥企業(有限合夥)) ^{Note 6}	684,016	–	0.35%	July 24, 2026
New Hope Medical Health Nanjing Investment Center (Limited Partnership) (新希望醫療健康南京投資中心(有限合夥))	5,662,889 (including 5,662,889 H Shares)	3.83%	2.93%	July 24, 2026
Kunming High-tech Nuotai Big Health Industry Investment Partnership Enterprise (Limited Partnership) (昆明高新諾泰大健康產業投資合夥企業(有限合夥)) ^{Note 7}	3,469,379 (including 3,469,379 H Shares)	2.35%	1.79%	July 24, 2026
Wuhan Hofon Jianmin Yichao Investment Partnership Enterprise (Limited Partnership) (武漢華方健民醫潮投資合夥企業(有限合夥)) ^{Note 7}	325,557 (including 325,557 H Shares)	0.22%	0.17%	July 24, 2026
Hangzhou Hofon Heyi Investment Management Partnership Enterprise (Limited Partnership) (杭州華方和頤投資管理合夥企業(有限合夥)) ^{Note 7}	867,343 (including 867,343 H Shares)	0.59%	0.45%	July 24, 2026
Nanjing Jiangbei Medical Innovation Industry Fund (Limited Partnership) (南京江北醫療創新產業基金(有限合夥)) ^{Note 8}	4,817,264 (including 4,817,264 H Shares)	3.26%	2.49%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Nanjing Jiangbei High-tech Industrial Development Equity Investment Fund (Limited Partnership) (南京江北高新技術產業發展股權投資基金(有限合夥)) ^{Note 8}	1,221,511	–	0.63%	July 24, 2026
Nanjing Qiruiyoukang Venture Capital Partnership (Limited Partnership) (南京其瑞佑康創業投資合夥企業(有限合夥)) ^{Note 8}	3,053,782 (including 1,526,891 H Shares)	1.03%	1.58%	July 24, 2026
Hangzhou Yuhang Longpan Health Medical Equity Investment Fund Partnership Enterprise (Limited Partnership) (杭州余杭龍磐健康醫療股權投資基金合夥企業(有限合夥))	4,662,821 (including 4,662,821 H Shares)	3.16%	2.41%	July 24, 2026
Shanghai Zhuangzhong Venture Investment Co., Ltd. (上海莊鍾創業投資有限公司)	3,941,250 (including 3,941,250 H Shares)	2.67%	2.04%	July 24, 2026
Shanghai Guohong Zhiyan Venture Investment Partnership Enterprise (Limited Partnership) (上海國鴻智言創業投資合夥企業(有限合夥))	3,664,534 (including 3,664,534 H Shares)	2.48%	1.90%	July 24, 2026
Shenzhen Capital Group Co., Ltd. (深圳市創新投資集團有限公司) ^{Note 9}	1,665,296 (including 832,648 H Shares)	0.56%	0.86%	July 24, 2026
Shenzhen Hongtu Medical Health Industry Equity Investment Fund Partnership (L.P.) (深圳紅土醫療健康產業股權投資基金合夥企業(有限合夥)) ^{Note 9}	1,665,296 (including 832,648 H Shares)	0.56%	0.86%	July 24, 2026
Xiamen Dyee Evergreen Venture Investment Partnership Enterprise (Limited Partnership) (廈門德屹長青創業投資合夥企業(有限合夥))	3,330,584 (including 3,330,584 H Shares)	2.25%	1.72%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Xinyu City Shangrun Investment Partnership Enterprise (Limited Partnership) (新余市上潤投資合夥企業(有限合夥)) ^{Note 10}	1,832,271 (including 1,832,271 H Shares)	1.24%	0.95%	July 24, 2026
Xinyu City Xinguolu Investment Partnership Enterprise (Limited Partnership) (新余市新國路投資合夥企業(有限合夥)) ^{Note 10}	666,110 (including 666,110 H Shares)	0.45%	0.34%	July 24, 2026
Xinyu Shangxuan Equity Investment Partnership (Limited Partnership) (新余上宣股權投資合夥企業(有限合夥)) ^{Note 10}	500,000	–	0.26%	July 24, 2026
Anhui Kunlu Venture Capital Partnership (Limited Partnership) (安徽昆路創業投資合夥企業(有限合夥)) ^{Note 10}	1,350,000	–	0.70%	July 24, 2026
Nanjing Kaitai Venture Investment Partnership Enterprise (Limited Partnership) (南京凱泰創業投資合夥企業(有限合夥))	774,579 (including 774,579 H Shares)	0.52%	0.40%	July 24, 2026
Gongqingcheng Jiuyou Shenghui Investment Management Partnership Enterprise (Limited Partnership) (共青城久友生暉投資管理合夥企業(有限合夥)) ^{Note 11}	1,258,157 (including 1,258,157 H Shares)	0.85%	0.65%	July 24, 2026
Gongqingcheng Jiuyou Shengrui Investment Management Partnership Enterprise (Limited Partnership) (共青城久友生瑞投資管理合夥企業(有限合夥)) ^{Note 11}	1,184,865 (including 1,184,865 H Shares)	0.80%	0.61%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
KPC Pharmaceuticals, Inc. (昆藥集團股份有限公司)	2,443,022 (including 2,443,022 H Shares)	1.65%	1.26%	July 24, 2026
CCBI Venture Capital Shenzhen Co., Ltd (建銀國際(深圳)創業投資有限公司)	2,275,954 (including 2,275,954 H Shares)	1.54%	1.18%	July 24, 2026
AJS Alphatech Limited	2,131,578 (including 2,131,578 H Shares)	1.44%	1.10%	July 24, 2026
Yellow River Delta Rongchang (Yantai) Venture Capital Partnership Enterprise (Limited Partnership) (黃河三角洲榮昌(煙台)創業投資合夥企業(有限合夥))	1,998,356 (including 1,998,356 H Shares)	1.35%	1.03%	July 24, 2026
Jiaxing Minglang No. 2 Equity Investment Fund Partnership Enterprise (Limited Partnership) (嘉興銘朗二號股權投資基金合夥企業(有限合夥))	1,832,271 (including 1,832,271 H Shares)	1.24%	0.95%	July 24, 2026
Guangdong Bozi Tongze No. 1 Equity Investment Partnership (Limited Partnership) (廣東博資同澤一號股權投資合夥企業(有限合夥)) (“Guangdong Bozi”) ^{Note 12}	1,665,296 (including 1,665,296 H Shares)	1.13%	0.86%	July 24, 2026
Nanjing Jingyong Medical Health Venture Investment Fund Partnership Enterprise (Limited Partnership) (南京景永醫療健康創業投資基金合夥企業(有限合夥))	1,589,744 (including 1,589,744 H Shares)	1.08%	0.82%	July 24, 2026
Gongqingcheng Ruiji Phase V Investment Partnership Enterprise (Limited Partnership) (共青城瑞吉五期投資合夥企業(有限合夥))	1,332,237 (including 1,332,237 H Shares)	0.90%	0.69%	July 24, 2026

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Truman Enterprises (Hong Kong) limited	1,332,237 (including 1,332,237 H Shares)	0.90%	0.69%	July 24, 2026
Jiaxing Tongren Hefu Equity Investment Partnership Enterprise (Limited Partnership) (嘉興同人合富股權投資合夥企業(有限合夥))	1,332,237 (including 1,332,237 H Shares)	0.90%	0.69%	July 24, 2026
Ningbo Lan Hui Investment Management Partnership Enterprise (Limited Partnership) (寧波攬慧投資管理合夥企業(有限合夥))	1,221,511 (including 610,756 H Shares)	0.41%	0.63%	July 24, 2026
Jiaxing Zhongying Zhonghui Venture Capital Partnership (Limited Partnership) (嘉興中贏眾匯創業投資合夥企業(有限合夥))	1,000,000 (including 1,000,000 H Shares)	0.68%	0.52%	July 24, 2026
Liang Jie (梁傑)	937,500 (including 937,500 H Shares)	0.63%	0.48%	July 24, 2026
Sun Yi (孫頤)	937,500 (including 937,500 H Shares)	0.63%	0.48%	July 24, 2026
Guangzhou Kaide Phase I Biopharmaceutical Industry Investment Fund Partnership (Limited Partnership) (廣州凱得一期生物醫藥產業投資基金合夥企業(有限合夥))	1,500,000	–	0.78%	July 24, 2026
Intellective Biologics (Suzhou) Limited (智享生物(蘇州)有限公司)	1,150,000	–	0.59%	July 24, 2026
Total	118,787,873	59.66%	61.43%	
<i>Notes:</i>				
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.				

2. *The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.*
3. *Each an investment arm of Ennovation Ventures (恩然創投);*
4. *Each an investment arm of Hankang Capital. The Company has applied for, and the Stock Exchange has granted, a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Hankang Entities, each a close associate of Suzhou Hankang, Beijing Hankang and Hankang SME, to permit the Company to allocate such Offer Shares in the International Offering to Hankang Entities. The allocation of Offer Shares to Hankang Entities is in compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Strict Compliance with the Companies (Winding up and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders” in the Prospectus for details.*
5. *Each an investment arm of Loyal Valley Capital. The Company has applied for, and the Stock Exchange has granted, (i) a waiver from strict compliance with Rule 10.04 of the Listing Rules and a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Loyal Valley Fund III, an existing shareholder of Company, and (ii) a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to LVC Entities, each a close associate of Loyal Valley Fund III, Shanghai Leyong and Shanghai Jishi Lemei, to permit the Company to allocate such Offer Shares in the International Offering to LVC Entities. The allocation of Offer Shares to LVC Entities is in compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Strict Compliance with the Companies (Winding up and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders” in the Prospectus for details.*
6. *Each an investment arm of Huaige Capital.*
7. *Each an investment arm of Hofon Capital.*
8. *Each a limited partnership controlled by Nanjing Jiangbei New Area Management Committee (Nanjing High-tech Industrial Development Zone Management Committee, Nanjing Area Management Committee of China (Jiangsu) Pilot Free Trade Zone) (南京江北新區管理委員會(南京高新技術產業開發區管理委員會、中國(江蘇)自由貿易試驗區南京片區管理委員會)).*
9. *Each ultimately controlled by the State-owned Assets Supervision and Administration Commission of Shenzhen Municipal People’s Government (深圳市人民政府國有資產監督管理委員會).*
10. *Each an investment arm of NSR Capital.*
11. *Both are investment arms of Jiuyou Capital.*
12. *The Company has applied for, and the Stock Exchange has granted, a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Bosera International, a close associate of Guangdong Bozi, to permit the Company to allocate such Offer Shares in the International Offering to Bosera International as a placee. The allocation of Offer Shares to Bosera International is in compliance with all the conditions under the consent granted by the Stock Exchange. For details, please refer to the section headed “Others/Additional Information” in this announcement below.*

Existing Shareholders (other than the AIC Parties and the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing^{Note 1}</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing^{Note 1}</i>	<i>Last day subject to the lock-up undertakings^{Note 2}</i>
Lu Dongcheng	7,023,307 (including 7,023,307 H Shares)	4.75%	3.63%	July 24, 2026
Total	7,023,307	4.75%	3.63%	
<i>Notes:</i>				
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.				
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.				

PLACEE CONCENTRATION ANALYSIS

<i>Placees*</i>	<i>Number of H Shares allotted</i>	<i>Allotment as % of International Offering (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)</i>	<i>Allotment as % of total Offer Shares (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)</i>	<i>Number of Shares held upon Listing</i>	<i>% of total issued share capital upon Listing (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)</i>
Top 1	2,915,500	13.99%	7.91%	16,485,596	8.53%
Top 5	11,437,800	54.90%	31.03%	25,007,896	12.93%
Top 10	16,847,000	80.86%	45.70%	30,417,096	15.73%
Top 25	22,786,700	109.37%	61.82%	48,929,621	25.30%

Note:

* Ranking of placees is based on the number of H Shares allotted to the placees.

H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	15,712,443	10.63%	30,688,820
Top 5	488,400	2.34%	1.32%	47,049,069	31.84%	71,695,321
Top 10	528,400	2.54%	1.43%	71,462,339	48.37%	97,625,255
Top 25	11,966,200	57.43%	32.46%	111,341,005	75.36%	152,028,063

Notes:

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

** Including H Shares allotted under the Hong Kong Public Offering and International Offering and among which, 16,027,200 H Shares were allotted under the Hong Kong Public Offering and 20,835,300 H Shares were allotted under the International Offering.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)
Top 1	0	0.00%	0.00%	15,712,443	30,688,820	15.87%
Top 5	3,403,900	16.34%	9.23%	43,837,216	81,157,610	41.97%
Top 10	3,403,900	16.34%	9.23%	71,292,543	110,129,601	56.95%
Top 25	10,172,000	48.82%	27.59%	111,212,101	153,564,455	79.42%

Notes:

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

** Including H Shares allotted under the Hong Kong Public Offering and International Offering and amongst which, 16,027,200 H Shares were allotted under the Hong Kong Public Offering and 20,835,300 H Shares were allotted under the International Offering.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 323,706 valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT POOL A	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
100	53,525	145 out of 53,525 to receive 100 Shares	0.27%
200	19,712	107 out of 19,712 to receive 100 Shares	0.27%
300	11,698	95 out of 11,698 to receive 100 Shares	0.27%
400	6,756	73 out of 6,756 to receive 100 Shares	0.27%
500	18,137	246 out of 18,137 to receive 100 Shares	0.27%
600	5,993	97 out of 5,993 to receive 100 Shares	0.27%
700	4,455	84 out of 4,455 to receive 100 Shares	0.27%
800	5,314	115 out of 5,314 to receive 100 Shares	0.27%
900	3,486	85 out of 3,486 to receive 100 Shares	0.27%
1,000	31,166	844 out of 31,166 to receive 100 Shares	0.27%
1,500	14,390	584 out of 14,390 to receive 100 Shares	0.27%
2,000	12,793	693 out of 12,793 to receive 100 Shares	0.27%
2,500	10,507	711 out of 10,507 to receive 100 Shares	0.27%
3,000	7,052	573 out of 7,052 to receive 100 Shares	0.27%
3,500	5,694	540 out of 5,694 to receive 100 Shares	0.27%
4,000	3,445	373 out of 3,445 to receive 100 Shares	0.27%
4,500	2,473	301 out of 2,473 to receive 100 Shares	0.27%
5,000	6,618	896 out of 6,618 to receive 100 Shares	0.27%
6,000	5,206	846 out of 5,206 to receive 100 Shares	0.27%
7,000	3,752	711 out of 3,752 to receive 100 Shares	0.27%
8,000	4,042	875 out of 4,042 to receive 100 Shares	0.27%
9,000	2,911	709 out of 2,911 to receive 100 Shares	0.27%
10,000	19,734	5,343 out of 19,734 to receive 100 Shares	0.27%
20,000	11,299	6,118 out of 11,299 to receive 100 Shares	0.27%
30,000	6,956	5,650 out of 6,956 to receive 100 Shares	0.27%
40,000	4,144	100 Shares plus 344 out of 4,144 to receive additional 100 Shares	0.27%
50,000	3,592	100 Shares plus 1,270 out of 3,592 to receive additional 100 Shares	0.27%
60,000	2,632	100 Shares plus 1,643 out of 2,632 to receive additional 100 Shares	0.27%
70,000	2,055	100 Shares plus 1,840 out of 2,055 to receive additional 100 Shares	0.27%
80,000	1,933	200 Shares plus 321 out of 1,933 to receive additional 100 Shares	0.27%
90,000	1,505	200 Shares plus 657 out of 1,505 to receive additional 100 Shares	0.27%
100,000	10,323	200 Shares plus 7,302 out of 10,323 to receive additional 100 Shares	0.27%
	<hr/>		
	303,298	Total number of Pool A successful applicants:	
		52,998	

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT POOL B	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
200,000	10,608	100 Shares plus 10,019 out of 10,608 to receive additional 100 Shares	0.10%
300,000	3,411	200 Shares plus 3,127 out of 3,411 to receive additional 100 Shares	0.10%
400,000	1,577	300 Shares plus 1,402 out of 1,577 to receive additional 100 Shares	0.10%
500,000	1,103	400 Shares plus 950 out of 1,103 to receive additional 100 Shares	0.10%
600,000	649	500 Shares plus 541 out of 649 to receive additional 100 Shares	0.10%
700,000	478	600 Shares plus 385 out of 478 to receive additional 100 Shares	0.10%
800,000	360	700 Shares plus 280 out of 360 to receive additional 100 Shares	0.10%
900,000	275	800 Shares plus 206 out of 275 to receive additional 100 Shares	0.10%
1,000,000	741	900 Shares plus 535 out of 741 to receive additional 100 Shares	0.10%
1,500,000	175	1,400 Shares plus 102 out of 175 to receive additional 100 Shares	0.10%
1,602,700	1,031	1,500 Shares plus 599 out of 1,031 to receive additional 100 Shares	0.10%
	<hr/> 20,408	Total number of Pool B successful applicants: 20,408	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Hong Kong Stock Exchange trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Reallocation and Offer Size Adjustment Option

As the Hong Kong Public Offering has been over-subscribed by more than 100 times of the number of the Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedure as disclosed in the paragraph headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation and Clawback” in the Prospectus has been applied.

The Offer Size Adjustment Option has been fully exercised, pursuant to which the Company is issuing and allotting 4,808,100 additional H Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering, at the Final Offer Price. All of the additional H Shares that would be allotted and issued by the Company pursuant to the full exercise of the Offer Size Adjustment Option will be allocated to the International Offering. Accordingly, the total number of Offer Shares finally available under the Global Offering (taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) that would be allotted and issued by the Company is 36,862,500 H Shares and the total issued share capital of the Company upon Listing (taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option) will be 193,362,500 Shares.

As a result of the above, the final number of Offer Shares under the Hong Kong Public Offering is adjusted to 16,027,200 H Shares, representing approximately 43.48% of Offer Shares initially available under the Global Offering (assuming the Over-allotment Option is not exercised), and the final number of Offer Shares under the International Offering is adjusted to 20,835,300 Shares, representing 56.52% of the total number of Offer Shares under the Global Offering (assuming the Over-allotment Option is not exercised).

Allocation of Offer Shares to an existing shareholder as placee (with waiver from strict compliance with Rule 10.04 of the Listing Rules and a written consent under paragraph 5(2) of the Placing Guidelines) and to close associates of existing Shareholders as placees (with prior written consent under Paragraph 5(2) of the Placing Guidelines)

Loyal Valley Fund III

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 10.04 of the Listing Rules to permit the Company to allocate such Offer Shares in the International Offering to Loyal Valley Fund III, an existing shareholder of Company. Please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemptions from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders” in the Prospectus for details.

LVC Entities and Hankang Entities

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a written consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to LVC Entities and Hankang Entities. Please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemptions from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders” in the Prospectus for details.

Bosera International

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to Bosera International. Bosera International is a close associate of Guangdong Bozi, an existing Shareholder of the Company. The allocation of Offer Shares to Bosera International is in compliance with all the conditions under the consent granted by the Stock Exchange, including but not limited to (i) the Company will comply with the public float requirements under rule 8.08(1) and 18A.07, and (ii) no preferential treatment in allocation was given to Bosera International.

Allocation of Offer Shares to connected clients with prior written consent under paragraph 5(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(1) of the Placing Guidelines to permit certain Offer Shares to be placed to connected clients of their connected distributors under the International Offering pursuant to the Placing Guidelines. Details of the placement to connected clients are set out below:

No.	Connected Distributor	Connected Client/Placee	Relationship with the Connected Distributor	Information of the Connected Client	Whether the Connected Client will hold the beneficial interest of the Offer Shares on a non-discretionary basis or discretionary basis for independent third parties	Number of Shares to be subscribed	Approximate % to the Offer Shares under the Global Offering (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)	Approximate % to the total issued share capital immediately following completion of the Global Offering (taking into account the full exercise of the Offer Size Adjustment Option and assuming no exercise of the Over-allotment Option)
1.	CLSA Limited (“CLSA”)	CSI	CSI is a member of the same group of companies as CLSA.	Please refer to Note 1	Non-discretionary basis for independent third parties	1,116,600	3.03%	0.58%
2.	CLSA	China AM HK	China AM HK is a member of the same group of companies as CLSA	Please refer to Note 2	Discretionary basis for independent third parties	60,000	0.16%	0.03%
3.	UBS AG Hong Kong Branch Wealth Management (“UBS WM”)	UBS AM	UBS AM is a member of the same group of companies as UBS WM	Please refer to Note 3	Discretionary basis for independent third parties	494,000	1.34%	0.26%

1. *CSI will act as the single counterparty of a back-to-back total return swap transaction (the “**CSI Back-to-back TRS**”) to be entered into by CSI in connection with a total return swap order (the “**CSI Client TRS**”) placed and fully funded by its ultimate clients (the “**CSI Ultimate Clients**”), by which CSI will pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients. CSI will hold the beneficial interest of the Offer Shares on behalf of the CSI Ultimate Clients on a non-discretionary basis. The CSI Ultimate Clients may exercise their early termination rights to terminate the CSI Client TRS at any time from the trade date of the CSI Client TRS which should be on or after the date on which the Offer Shares are listed on the Stock Exchange. Upon the final maturity or termination of the CSI Client TRS by the CSI Ultimate Clients, CSI will dispose of the Offer Shares on the secondary market and the CSI Ultimate Clients will receive a final termination amount of the CSI Back-to-back TRS which will have taken into account all the economic returns or economic loss in relation to the Offer Shares and the fixed amount of transaction fees of the CSI Back-to-back TRS and the CSI Client TRS. CSI will not exercise the voting right of the Offer Shares during the terms of the CSI Back-to-back TRS.*

To the best knowledge of CSI and after making all reasonable enquiries, each of the CSI Ultimate Clients is an independent third party of the Company, its subsidiaries and substantial shareholders, CSI, CLSA and the companies which are members of the same group of CLSA.

2. *China AM HK will subscribe for and hold the Offer Shares as a placee under the International Offering in accounts in its capacity as the discretionary fund manager managing assets on behalf of its underlying clients. To the best knowledge of China AM HK after due enquiry, each of the underlying clients of China AM HK is an independent third party of the Company, its subsidiaries, China AM HK and CLSA and the companies which are members of the same group of CLSA.*
3. *UBS AM, in the capacity as the investment advisor to and delegate of the investment manager for and on behalf of certain funds, segregated accounts and/or mandates (“**Underlying Clients**”), will subscribe for the Offer Shares for and on behalf of its Underlying Clients on discretionary basis.*

To the best knowledge of UBS AM, each of its underlying clients is an independent third party of the Company, its subsidiaries and substantial shareholders, UBS AM and UBS WM and the companies which are members of the same group of UBS WM.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated July 17, 2025 issued by Nanjing Leads Biolabs Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Friday, July 25, 2025).*

PUBLIC FLOAT

Immediately after the completion of the Global Offering, after taking into account of the full exercise of the Offer Size Adjustment Option and without taking into account of the Over-allotment Option, an aggregate of 125,445,815 H Shares, representing approximately 64.88% of the issued share capital of the Company will be held in public hands. Therefore, the number of H Shares held in public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules. Based on the Offer Price of HK\$35.00 per Share, the Company will have a market capitalization of at least HK\$375 million held by the public at the time of the Listing as required under Rule 18A.07 of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering: (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the H Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Friday, July 25, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting — Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, July 25, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Friday, July 25, 2025 (Hong Kong time). The H Shares will be traded in board lots of 100 H Shares each, and the stock code of the H Shares will be 9887.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 24, 2025

As of the date of this announcement, the board of directors of the Company named in the Prospectus comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as proposed independent non-executive directors.